Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 16/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762823 | 0.90 | FGFR1 (0.41) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL742979 | 0.88 | LMNA (0.39) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL939373 | 0.86 | FGFR1 (0.42) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL3618756 | 0.83 | AURKB (0.45) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL940569 | 0.83 | FGFR1 (0.39) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL3619154 | 0.81 | RIPK1 (0.49) | RIPK1AURKAAURKB | |
| SCHEMBL743360 | 0.80 | FGFR1 (0.38) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL3620899 | 0.80 | FLT1 (0.51) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL741930 | 0.79 | FGFR1 (0.37) | FGFR1RIPK1AURKAAURKB | |
| SCHEMBL940266 | 0.79 | PTGES (0.38) | FGFR1RIPK1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | FGFR1 776/4885RIPK1 333/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.